Baron Wealth Management LLC Has $782,000 Stake in Abbott Laboratories $ABT

Baron Wealth Management LLC grew its position in Abbott Laboratories (NYSE:ABT) by 6.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,750 shares of the healthcare product maker’s stock after purchasing an additional 370 shares during the quarter. Baron Wealth Management LLC’s holdings in Abbott Laboratories were worth $782,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Seneca House Advisors grew its position in shares of Abbott Laboratories by 4.1% during the 2nd quarter. Seneca House Advisors now owns 2,636 shares of the healthcare product maker’s stock worth $359,000 after purchasing an additional 104 shares in the last quarter. StrongBox Wealth LLC grew its position in shares of Abbott Laboratories by 11.3% during the 2nd quarter. StrongBox Wealth LLC now owns 29,652 shares of the healthcare product maker’s stock worth $4,033,000 after purchasing an additional 3,011 shares in the last quarter. Aaron Wealth Advisors LLC grew its position in shares of Abbott Laboratories by 3.0% during the 2nd quarter. Aaron Wealth Advisors LLC now owns 14,719 shares of the healthcare product maker’s stock worth $2,002,000 after purchasing an additional 425 shares in the last quarter. Divergent Planning LLC acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth approximately $4,033,000. Finally, Balefire LLC grew its position in shares of Abbott Laboratories by 73.6% during the 2nd quarter. Balefire LLC now owns 6,145 shares of the healthcare product maker’s stock worth $836,000 after purchasing an additional 2,606 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of analyst reports. Leerink Partners initiated coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a “market perform” rating and a $143.00 target price on the stock. Evercore ISI upped their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Morgan Stanley upped their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. BTIG Research cut their price target on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a report on Friday, July 18th. Finally, Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and upped their price target for the stock from $143.00 to $145.00 in a report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $144.47.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Trading Up 1.1%

NYSE:ABT opened at $132.76 on Wednesday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $231.06 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 2.49 and a beta of 0.69. The firm has a fifty day simple moving average of $130.35 and a two-hundred day simple moving average of $131.22. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. The business had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the company posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.